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Huntington’s disease (HD) is a monogenic autosomal dominant, fatal disorder due to CAG
trinucleotide expansion in exon 1 of the HD gene (HTT) (The Huntington’s Disease Collaborative
Research Group, 1993; Figure 1A). Nowadays, there is no cure or effective treatment for the disease
which presents with motor, cognitive and psychiatric dysfunction. Although typically conceived
as a “neurodegenerative disease,” mainly affecting the GABAergic medium-sized spiny neurons
(MSN) of the striatum and deep layers of the cortex (Rosas et al., 2003), an increasing body of
evidence has surfaced indicating that abnormal neurodevelopment might also have a crucial role
in HD (Mehler and Gokhan, 2000, 2001; Humbert, 2010). Neurodegenerative diseases have been
classically defined as chronic and progressive disorders of the nervous system affecting neurologic
and behavioral functions, which start with specific biochemical changes that ultimately lead to
distinct histopathologic and clinical syndromes. On the contrary, neurodevelopmental disorders
result from an anomaly of brain maturation, during fetal or early postnatal life, which is postulated
to alter the structure and/or function of neuronal and synaptic populations (Harrison, 1995).
This opinion piece discusses the existing evidences from HD patients and HD model systems
for a neurodevelopmental component to the neurodegenerative processes of Huntington’s Disease
pathophysiology.
The first and most striking observations come from multi-national neuropathological and
neuroimaging studies of prodromal HD, reporting clear brain changes decades prior to onset of
disease: specifically, smaller head circumference (Lee et al., 2012), caudate and putamen atrophy
(Nopoulos et al., 2007; Paulsen et al., 2010), striatal and cortical white matter abnormalities
including increased density of oligodendrocytes (Gómez-Tortosa et al., 2001) and cortical thinning
(Nopoulos et al., 2007) were described. Moreover, subtle but significant defects in cognitive
(Solomon et al., 2007), behavioral (Duff et al., 2007), and motor function (Hinton et al., 2007) have
been identified in prodromal HD subjects long before a clinical diagnosis. While these observations
might be linked to early neuronal degeneration, the other plausible interpretation is that they
represent manifestations of subtle altered development that prime specific areas and neuronal
subpopulations of the brain to later catastrophic consequences (Figure 1).
Further indications come from studies of mouse models with inactivation of the HD orthologue
gene Htt. Huntingtin protein, in fact, is expressed in all cell types of the body, at all developmental
stages and it has crucial roles during development and neurogenesis (Figure 1B). Parallel
studies have shown that complete lack of huntingtin in mice results in embryonic lethality
with developmental arrest just post gastrulation (Duyao et al., 1995; Zeitlin et al., 1995), while
severe reduction of huntingtin levels in heterozygous, Htt hypomorphic mice or Htt conditional
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knock-out neuronal subpopulations manifests in abnormal
brain development, cognitive and motor abnormalities (Nasir
et al., 1995; White et al., 1997; Auerbach et al., 2001; Godin
et al., 2010). Given this key role of wild-type huntingtin
during development, it is not surprising that studies on genetic
engineered mice expressing Htt CAG-expansion pathogenic
mutations show subtle molecular and structural deficits that
portend altered developmental processes and precede the
occurrence of neurological symptoms and signs of cell death
(Luthi-Carter et al., 2000; Wheeler et al., 2000; Fossale et al.,
2011). Specifically, even in Hdh knock-in mice, representing a
faithful genetic replica of the human HD mutation [expressing
full-length mutant huntingtin at endogenous levels from the
native promoter at the Htt locus], although usually presenting
milder molecular and behavioral phenotypes compared to HD
transgenic and fragment lines, one single copy of the mutant Htt
allele is sufficient to cause nuclear accumulation of full-length
mutant huntingtin in MSN as early as 3 weeks of age (Wheeler
et al., 2000), molecular changes in pathways related to energy
metabolism and cAMP levels, RNA metabolism (Gines et al.,
2003) and measurable transcription/translation dysfunctions
(Fossale et al., 2011) at 3 and 10 weeks of age, well before the
onset of any overt pathological alteration. Strikingly, in the
same Hdh Q111 knock-in HD mouse model, deregulation of the
temporal and spatial profiles of striatal neurogenesis [delayed
cell cycle exit and transient aberrant expression of pluripotency
markers in MSN-generating neural stem cells] (Molero
et al., 2009) may expose striatal precursors to inappropriate
molecular cues driving them into aberrant programs of
neuronal differentiation, thus reinforcing the notion that altered
neurodevelopmentmight forecast laterMSN susceptibility in HD
(Figure 1C).
Additional consistent observations emerged from studies
using mouse embryonic stem cells and neural committed
progenitors bearing Htt CAG-expansion mutations (Jacobsen
et al., 2011; Conforti et al., 2013; Biagioli et al., 2015) as well
as patient-derived induced pluripotent stem cells (iPSCs)
(The HD iPSC Consortium, 2012), showing measurable
molecular differences and a series of expanded CAG-associated
phenotypes that point toward a central role of wild-type and
mutant huntingtin in signal transduction, axonal guidance,
synaptic transmission and neurodevelopment. Specifically,
unbiased “- omics” analyses, probing transcriptomic, chromatin
modifications and DNA methylation status in these cells
and their neuronal derivatives, support the hypothesis that
wild-type and mutant huntingtin might affect key chromatin
regulators such as DNA and histone methyl transferases, and
demethylases [Polycomb Repressive Complex 2 (PRC2), Mixed
Lineage Leukemia 1–4, JARID1, REST, HYPB-SETD2] (Lee
et al., 2013; Ng et al., 2013; Biagioli et al., 2015). In fact, a
growing body of evidence suggests that alterations of epigenetic
modifications constitute a basic molecular mechanism caused
by the HD mutation and responsible for early features of
the pathological process. Strikingly, most of these epigenetic
regulators, i.e., Polycomb Complexes, but also other histone
post-transcriptional modifications enzymes, have important
roles during transition from pluripotency to differentiation and
neural development, in particular (Jepsen et al., 2007). While
FIGURE 1 | CAG expansion in the human HTT gene leads to
Huntington’s Disease (HD): possible contribution of altered non-coding
RNA transcription and aberrant developmental processes are
described. (A) Top pie charts report the proportion of coding and noncoding
RNAs in the human genome (Alexander et al., 2010). Highlighted in the coding
portion of the genome, the Huntington’s Disease gene (HTT ). Wild type or
expanded CAG lengths are indicated by sepia and gray colors, respectively.
Bottom pie charts summarize the relative contribution of single classes of
non-coding RNAs (Baker, 2011) to normal (sepia) or diseased (gray) organism
physiology. The contribution of non-coding RNA transcription to HD process is
still not fully dissected. (B) Schematic representation of human development at
different stages [blastocyst (5 days) and 25 days embryos, 100 days and 5
months fetuses and adult organism] is shown. Normal (sepia) and mutant
huntingtin [expanded HTT gene] (grayscale) expression is found in the whole
organism at any given developmental stage (MacDonald et al., 2003; Gusella
and MacDonald, 2006). Molecular mechanisms (miRNAs, lncRNAs, alterative
splicing, histone modifications and chromatin remodeling) acting since
conception in the organism bearing the mutation are represented by the gray
area. (C) A simplified representation of HD brain development is shown.
Developmental stages as in (B). Different color’s shades denote specific brain
regions such as telencephalon, diencephalon, midbrain, and hindbrain which
develop differently to originate adult brain structures. Light gray lines across
the head designate coronal sections unveiling inner brain organization, while
puzzle pieces represent various cell types constituting each brain district. It is
evident that the presence of mutant huntingtin (expanded HTT gene) places
any cell of the organism—and of the brain in particular—in a “different
biological state” with subtle cellular and tissue development alterations that
culminate in the overt symptoms appearing in adult life. The changes induced
by the expression of CAG-repeat HTT expansion compromise
MSN-generating stem cells specification and prime MSN to adult neuronal
degeneration (Molero et al., 2009; Humbert, 2010).
Frontiers in Neuroscience | www.frontiersin.org 2 January 2016 | Volume 9 | Article 509
Kerschbamer and Biagioli Huntington’s Disease as Neurodevelopmental Disorder
the exact mechanisms of this “huntingtin chromatin function”
are not entirely known, some evidence has accumulated
suggesting that wild-type and CAG-expanded huntingtin may
interact, directly or indirectly, with epigenetic co-regulators
and alter their activity (Seong et al., 2010). Interestingly, the
DNA methylation pattern of several promoter regions of
genes involved with pluripotency and neural differentiation
(Sox2, Pax6, Nes) was found significantly reduced in presence
of mutant huntingtin (Ng et al., 2013), while the histone
methylation status of a class of developmentally-regulated
bivalent promoters associated with “Regulation of Neurogenesis”
and “Stress Signaling and Apoptosis” was altered following the
expression of CAG-expanded Htt alleles (Biagioli et al., 2015).
Thus, huntingtin protein might subtly but consistently alter
different aspects of chromatin regulation and transcription
during neural development and specification, explaining
the pleiotropic, subtle yet deleterious, effects of mutant
huntingtin observed throughout the life of an HD individual
(Figures 1B,C).
Parallel to alterations in the coding portion of the genome,
a growing number of studies is recently showing deregulation
of different classes of non-coding RNAs (ncRNAs)—microRNAs
(miRNAs), long non-coding RNAs (lncRNAs), piwi-interacting
RNAs (piRNAs), circular RNAs (circRNAs)—suggesting that they
may have a relevant impact on disease onset/progression. A large
percentage of ncRNAs physically interact with various chromatin
regulatory proteins, including PRC2, and other “readers/writers,
and erasers” of chromatin modifications, thus activating
or repressing gene expression via a chromatin recruitment
mechanism. The first, intriguing example of such regulatory
network is the mammalian X-chromosome inactivation, where
the finely regulated expression of Xist lncRNA is able to
recruit PRC2 to the specific genomic location of the silenced
X chromosome to mediate transcriptional repression. Recently,
systematic studies exploring ncRNA function have shown
their involvement in many biological processes also related to
embryonic development and neurogenesis (Qureshi and Mehler,
2012, Sauvageau et al., 2013). Particularly, several miRNAs, but
also lncRNAs have been reported to be enriched in the brain
and have key roles during transition from neural commitment
to terminal differentiation (Makeyev et al., 2007; Sauvageau
et al., 2013). Importantly, miRNAs might also target neuronal-
specific transcriptional regulators (i.e., REST and co-REST) as
well as brain-enriched alternative-splicing factors, thus affecting
synaptic activity and neuronal function (Makeyev et al., 2007;
Packer et al., 2008). Mutant huntingtin expression has been
correlated with alterations in REST cellular localization and
dysregulation of REST-regulated miRNAs (miR-9 and miR-
124) levels (Packer et al., 2008). Specifically, miR-9 and miR-
124 levels were shown to be reduced in the cortical areas of
HD post mortem brains where genes related to neurogenesis
were highly overrepresented (Hodges et al., 2006). Moreover,
a recent genome-wide screen of miRNAs in post mortem
brains highlighted miRNAs that were differentially expressed
between normal and HD subjects (Hoss et al., 2014). The vast
majority of these miRNAs are highly connected with HOX
clusters, a well-studied family of transcription factors, involved
in early brain development, contributing to anterior-posterior
positional establishment. HOX genes and HOX-related miRNAs
are tightly regulated by PRC2 proteins and are found to be altered
following mutant huntingtin expression (Seong et al., 2010).
Although the role of development-specific miRNAs and HOX
genes in the adult HD brain is still unclear, one interpretation
might suggest aberrant brain development following mutant
huntingtin expression, while, a second plausible explanation
might invoke a reactivation of developmental programs in
the later phases of HD degenerative process where surviving
and neurogenic hints try to counteract generalized neuronal
loss.
MiRNAs, however, are not the only class of ncRNAs with
developmental potential to be dysregulated in HD. Several
additional studies, in fact, report altered expression levels of
known lncRNAs TUG1, NEAT1, MEG3, and DGCR5 in the
brains of HD patients (Johnson, 2012). MEG3, in particular,
is reported to be a REST target with a dynamic expression
during development of the nervous system and associated with
PRC2 chromatin regulator, thus supporting a role for chromatin
regulation, non-coding transcription and neurodevelopment in
HD pathogenesis.
Other classes of ncRNA (pi-RNAs and circRNAs), associated
with chromatin remodeling factors and epigenetic modulators,
have a clear role during neural development and differentiation,
however their regulation upon expression of mutant huntingtin
has not been analyzed yet.
The analysis of non-coding RNA transcription and its
interplay with chromatin regulation in the context of human
neurological disease presents several challenges especially related
to the complexity of ncRNAs in the brain. In fact, the
annotation, identification and functional characterization of
ncRNAs continue to be puzzling because of the lack of a
complete understanding of functional domains, their generally
low expression levels, and the poor knowledge of their regulatory
regions (Esteller, 2011). International initiatives such as the
Encyclopedia of DNA Elements (ENCODE) or the generation
of knock-out mice for specific ncRNAs (Sauvageau et al., 2013,
Goff et al., 2015) represent the first effort to understand the
functional relevance of ncRNAs in the organism (and brain)
physiology and disease. Additional studies in this direction as
well as new and powerful genomic and bioinformatic tools
will be crucial to dissect the complexity of ncRNA brain
transcriptome to understand how the interaction between
epigenome and transcriptome will contribute to disease onset
and progression and shed light on possible new paths to
therapeutic intervention.
In conclusion, it’s time to rethink the simple view of
Huntington’s Disease as a merely neurodegenerative disorder
to include the idea that expression of the single copy of the
CAG-expanded HTT allele (Figure 1A) is also sufficient to
subtly alter development from conception. The “HD organism”
is, at any developmental time point, different from the “not-
HD counterpart” (Figures 1B,C). Like in a puzzle where the
HTT-CAG mutation forces pieces to fit where they do not
belong, similarly subtle developmental differences may give
rise to a different panoply of adequately functioning units
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which may last for a long time but ultimately not allow the
same flexibility with aging, thus aberrant neurodevelopment
might lead to disorganization and dysconnectivity of neurons
and subsequent susceptibility to neurodegenerative processes
(Figures 1B,C). Essential corollaries of this model are not
only new approaches to the understanding of the altered
pathologic process, but also new strategies of therapeutic
intervention/prevention. In fact, the recent identification of
genetic factors that are able to modify the age of onset of HD
patients, indicate that the HD pathologic process is modifiable
prior to clinical diagnosis (Genetic Modifiers of Huntington’s
Disease (GeM-HD) Consortium, 2015), thus representing a
proof-of-principle of a strategy that is predicated upon the idea
that intervening before onset of clinical signs is likely to be most
effective to finally ameliorate patients quality of life and/or life
expectancy.
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